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Purpose: The aim of the study was to evaluate the long-term 24-
hour intraocular pressure (IOP) eﬃcacy of travoprost mono-
therapy in primary open-angle glaucoma patients.
Patients and Methods: A total of 36 previously untreated primary
open-angle glaucoma patients were enrolled in this 5-year study.
Patients underwent an untreated 24-hour IOP evaluation. Sub-
sequently all patients were assigned to topical therapy with trav-
oprost 0.004% eye-drops preserved with benzalkonium chloride
(Travatan, Alcon Laboratories Inc., Fort Worth, TX) administered
once in the evening (8:00 PM) in both eyes. All patients were then
scheduled for a 24-hour IOP assessment approximately 12 months
after the baseline visit. This schedule of follow-up was maintained
for the whole duration of the trial. The predetermined range of
target IOP reduction selected in this cohort of patients ranged
between 20% and 30%.
Results: A total of 34 patients completed all phases of the inves-
tigation. The mean survival time was 57.3±2.0 months and the
cumulative survival rate was 0.82±0.6 at 60 months. Travoprost
reduced the mean 24-hour IOP from 23.4±1.7mm Hg at baseline
to 16.8±2.4mm Hg (28.4%), 16.8±2.5mm Hg (28.1%),
16.8±2.4mm Hg (28.5%), 16.7±2.5mm Hg (28.6%), and
16.9±2.4mm Hg (27.8%), respectively at the end of the ﬁrst,
second, third, fourth, and ﬁfth year follow-up. No drug-related
serious adverse events were registered during the study.
Conclusions: The present study demonstrated the long-term 24-
hour eﬃcacy of travoprost for the treatment of primary open-angle
glaucoma.
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Reduction of intraocular pressure (IOP) is the only cur-rently available, evidence-based management strategy
in patients aﬀected with primary open-angle glaucoma
(POAG). Most POAG patients will require lifelong medical
therapy to avoid visual loss. The decision to select medical
therapy options relies primarily on the eﬃcacy of the
available medications in various therapeutic trials. Sadly,
most published studies only evaluate the short-term, day-
time eﬃcacy of medical therapy.
Prostaglandin analogues have become a popular ﬁrst-
line therapy option for lowering IOP in POAG owing to
their superior 24-hour eﬃcacy,1–6 convenient once-a-day
administration,5 and favorable systemic safety proﬁle.7
Travoprost is a synthetic prostaglandin F2a analogue that
exerts its IOP-lowering eﬀect through the prostaglandin FP
receptors situated at the ciliary muscle8 and the trabecular
meshwork.9 Travoprost is increasingly becoming a popular
ﬁrst-line monotherapy option for POAG patients10 as there
is cumulative evidence suggesting good quality of short-
term 24-hour IOP control with low ﬂuctuation, especially
with evening administration.11–13 However, although sev-
eral controlled studies have demonstrated the daytime
short-term eﬃcacy of travoprost monotherapy,14–16 little is
currently known about its long-term eﬃcacy.
As POAG is a 24-hour, lifelong disease, an ideal anti-
glaucoma medication should be successful in reducing IOP
during day and night.4,17 Importantly, 24-hour studies have
conﬁrmed that 24-hour IOP monitoring can signiﬁcantly
modify individualized glaucoma care in many glaucoma
patients.18,19 A few 24-hour studies have investigated trav-
oprost eﬃcacy over a period of up to 4 months,11–13,20 but
to date no evidence is available for the long-term 24-hour
eﬃcacy of travoprost monotherapy in glaucoma.
Therefore, the primary aim of this study was the
evaluation of the long-term 24-hour IOP eﬃcacy obtained
by travoprost monotherapy, used as a ﬁrst-line therapy
during a 5-year follow-up period. A secondary aim was to
investigate the survival rate without progression of a
POAG cohort treated with travoprost monotherapy.
MATERIALS AND METHODS
This was a prospective, open label, single-arm study
carried out at the Glaucoma Service of the Department of
Ophthalmology of the University of Brescia, Italy. The
research protocol adhered to the tenets of the Declaration
of Helsinki and was approved by the Institutional Review
Board of the University of Brescia, Italy. Enrolled patients
provided a written informed consent to participate in the
trial before any study-related activities were carried out.
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Participants
This study enrolled newly diagnosed, previously
untreated POAG patients who exhibited characteristic
glaucomatous disc damage and visual ﬁeld loss between
January and November 2005. Eligibility criteria were: age
above 45 years, no previous ocular surgery other than
uncomplicated phacoemulsiﬁcation cataract surgery per-
formed at least 6 months before entering the study, open-
angle by gonioscopy (grades III and IV according to the
Shaﬀer classiﬁcation), untreated IOP between 21 and
35mm Hg at 10:00 AM±1 hour veriﬁed by 2 separate
measurements (enrollment IOP).
Exclusion criteria for ophthalmic conditions were: any
type of glaucoma other than POAG; corneal or other
anatomic conditions making applanation tonometry unre-
liable; central corneal thickness r500 mm or Z600 mm;
signs or history of macular edema, herpetic, or other ocular
inﬂammatory disease; history of allergy or adverse event
related to the study medication; history or suspicion of
poor adherence to medical therapy; best-corrected visual
acuity <0.4 (Snellen); cup-to-disc ratio >0.7; mean devi-
ation (MD) worse than 15 dB in Humphrey 24-2 SITA
standard perimetry (Humphrey Visual Field Analyzer; Carl
Zeiss Meditec Inc., Dublin, CA); or the possibility of sig-
niﬁcant visual deterioration and optic nerve damage due to
participation to the study according to the principal
investigator’s judgment. Patients were also excluded if they
were unable to understand the study procedures, give
informed consent, or were using systemic corticosteroids.
Assessments
During an initial eligibility visit, all qualiﬁed patients
underwent a detailed ophthalmic examination and their
ocular and systemic clinical data were recorded. Study
participants were admitted at the University Ophthalmol-
ogy Clinic of Brescia, Italy, for an untreated 24-hour IOP
evaluation (baseline visit) with Goldmann tonometry. The
IOP was recorded at 10:00 AM, 2:00 PM, 6:00 PM, 10:00 PM,
2:00 AM, 6:00 AM, and 10:00 AM (±1h). The day before the
24-hour IOP assessment, a reliable 24-2 SITA standard
visual ﬁeld test was performed (Humphrey Visual Field
Analyzer; Carl Zeiss Meditec Inc.).
Subsequently all study patients were assigned to top-
ical therapy with travoprost 0.004% eye-drops preserved
with benzalkonium chloride (Travatan, Alcon Laboratories
Inc.) administered once in the evening (8:00 PM) in both
eyes. To ensure that the target IOP was reached, according
to the principal investigator’s judgment, a safety visit was
performed approximately 4 weeks after treatment ini-
tiation. The predetermined range of target IOP reduction
selected in this cohort with travoprost monotherapy ranged
between 20% and 30%. After this visit, all patients were
scheduled for a visit approximately 6 months after the
baseline visit at 10:00 AM±1 hour, as well as a 24-hour IOP
assessment approximately 12 months after the baseline
visit. This schedule of follow-up was maintained for the
whole duration of the trial. A comprehensive clinical
examination was performed at each visit. Enrolled patients
continued on travoprost monotherapy as long as their
target IOP was successfully maintained. Calibrated Gold-
mann tonometers were used throughout the duration of the
trial by a clinician masked to the previous baseline or
treated IOP data.
Statistics
The primary endpoint of the study was the mean
24-hour IOP measured at annual intervals. Only 1 eye per
patient was included in the analysis. The mean values for
24-hour IOP, daytime IOP, and nocturnal IOP were
obtained from every 24-hour IOP curve. Areas under the
curve (AUCs) were calculated for each variable, using a
trapezoidal rule. The trend over time for each variable was
evaluated by means of an analysis of variance model for
repeated measures, whereas a paired t test was used for
comparison of variables at each time-point with baseline
values. A Bonferroni approach was adopted to allow for
multiple tests: considering an a level of 0.05, statistical
signiﬁcance was set to 0.01, calculating as 0.05 divided for 5
comparisons. In these analyses, the approach of the last
value carried forward was applied for patients who did not
complete the study.
Failure was deﬁned as withdrawal of a patient from
the study, due to either failure to reach the target IOP set
upon enrollment or when reliable evidence of progression
existed, necessitating the introduction of adjunctive medical
therapy. The percentage of patients meeting target IOP at
every annual time-point was calculated. The Kaplan-Meier
survival method was used to describe the cumulative inci-
dence of travoprost monotherapy failure throughout the 5
years of the study. The mean survival time and cumulative
survival rate at 60 months were computed. An intent-to-
treat approach was applied for the analysis.
Univariate Cox regression analysis was performed to
evaluate age, MD, pattern standard deviation, baseline 24-
hour IOP, treated 24-hour IOP ﬂuctuation, and treated 24-
hour peak IOP as risk factors for progression/failure.
Treated 24-hour IOP ﬂuctuation was deﬁned as the SD of
the IOPs recorded during the treatment phase of the study
and reported in mm Hg. Treated IOP peak was deﬁned
as the mean of peak IOPs (ie, highest point in the range of
the 24-hour pressure curve) computed for each 24-hour
assessment during the treatment phase of the study.
Descriptive statistics were calculated for every variable and
variables were compared between nonfailure and failure
group of patients using an independent t test. Hazard ratios
(HR) for failure were reported for each putative factor in
the univariate analysis.
RESULTS
Thirty-six POAG patients were enrolled in this 5-year
study. Thirty-four patients completed all phases of the
investigation, whereas 2 patients were lost to follow-up,
both at approximately 48 months. Six patients were with-
drawn from the study because their target IOP could not be
reached at some stage, or because of reliable evidence of
progression (Fig. 1). Respectively 97.2%, 97.2%, 94.4%,
94.4%, and 94.4% of patients met their target IOP at ﬁrst,
second, third, fourth, and ﬁfth year of follow-up. For the
whole study population, the mean survival time was
57.3±2.0 months and the cumulative survival rate was
0.82±0.6 at 60 months. Table 1 shows the general features
of the patients included.
Travoprost reduced the mean 24-hour IOP from
23.4±1.7mm Hg at baseline to 16.8±2.4mm Hg
(28.4%), 16.8±2.5mm Hg (28.1%), 16.8±2.4mm Hg
(28.5%), 16.7±2.5mm Hg (28.6%), and 16.9±2.4mm
Hg (27.8%), respectively at the end of the ﬁrst, second,
third, fourth, and ﬁfth year of follow-up (Fig. 2). The mean
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24-hour IOP and calculated AUCs were signiﬁcantly lower
than baseline untreated values at each annual time-point of
evaluation (P<0.01), whereas no signiﬁcant diﬀerences
were found among yearly time-points during follow-up
(P>0.05) (Tables 2, 3).
The mean daytime and nocturnal IOP values at base-
line and at each yearly follow-up time-point are shown
in Tables 2 and 3. The trend of daytime and nocturnal IOP
over time is illustrated in Figure 2. Overall, daytime IOP,
nocturnal IOP, and their respective calculated AUCs, were
signiﬁcantly lower than baseline values at each yearly time-
point analyzed (P<0.01). No signiﬁcant diﬀerence was
documented for these parameters between yearly time-
points during the 5-year follow-up (P>0.05). No sig-
niﬁcant diﬀerences were detected between nocturnal and
diurnal IOP reductions induced by travoprost at each
annual time-point analyzed (P>0.05).
Univariate Cox regression analyses revealed no sig-
niﬁcant eﬀect of age (P=0.53), MD (P=0.76), pattern
standard deviation (P=0.97), and treated 24-hour IOP
ﬂuctuation (P=0.53) upon the risk of failure during the 5-
year follow-up period. Only the mean untreated 24-hour IOP
and treated 24-hour IOP peak values were found to be risk
factors for predicting travoprost treatment failure (HR: 1.9,
P<0.01 and HR: 1.03, P<0.01, respectively) (Table 4).
Treatment-related adverse events during the 5-year
course of the study are presented in Table 5. The most
common travoprost-related adverse events were iris
hyperchromia, seen in 10 patients (27.7%) and ocular
hyperaemia seen in 3 patients (8.3%). No drug-related
serious adverse events were registered during the study.
DISCUSSION
Topical therapy for glaucoma should be eﬀective in
maintaining a sustained IOP reduction over the long term.21,22
Although travoprost monotherapy has shown a meaningful
IOP eﬃcacy in the short term,11–16 there is limited information
on the long-term eﬃcacy (Z12mo).23 However, previous
clinical trials with latanoprost monotherapy, another prosta-
glandin analogue, have established a long-lasting daytime
hypotensive eﬀect with little evidence of tachyphylaxis, for up
to 4 years.24–28 This is further corroborated by the present
long-term 24-hour study, which documented consistent IOP
eﬃcacy with travoprost monotherapy in POAG patients dur-
ing the 5-year follow-up period.
The present 24-hour investigation observed that a
relatively high proportion (82%) of POAG patients reached
and maintained a predetermined, individualized target IOP
reduction between 20% and 30% with travoprost mono-
therapy during a 5-year follow-up period. Similarly, a
multicenter study on POAG patients treated with latano-
prost monotherapy reported satisfactory IOP control in the
vast majority of their patients (86%), but this was with a
shorter 2-year follow-up.29
To the best of our knowledge, this is the ﬁrst study to
monitor the long-term 24-hour IOP eﬃcacy with any
medication, or therapy option. Interestingly, the eﬃcacy
results of the present long-term 24-hour investigation
(27.8% to 28.6%) compare well with the available short-
term evidence for travoprost reported to date. A recent
meta-analysis by Stewart et al1 investigating the short-term
24-hour eﬃcacy of topical monotherapy agents reported
that travoprost reduced the mean 24-hour IOP by 27%
from untreated baseline. Further, Konstas et al11,12 in 2
separate trials reported travoprost to reduce the mean 24-
hour IOP by 26.7% and 26.3%, respectively. In another
short-term study by Orzalesi et al,13 travoprost reduced the
mean 24-hour IOP by 27.4%. The short-term 24-hour
eﬃcacy reported by these studies is fairly similar to the
long-term 24-hour eﬃcacy documented by the present
study. It seems that the long-term 24-hour travoprost eﬃ-
cacy is only slightly greater than that reported over the
short-term (with up to 3mo follow-up). Possible reasons for
this small diﬀerence include the mechanism of action of
TABLE 1. Characteristics of Studied Patients
Patients (n=36)
Sex (Male/Female) 20/16
Pseudophakia (n) 21
Mean±SD Range
Age (y) 69±10.9 52-85
IOP at enrollment (10 AM±1h)
(mm Hg)
24.3±2.74 20-34
Visual ﬁeld mean deviation at
enrollment (dB)
5.07±2.15 2.52-10.13
IOP indicates intraocular pressure.
FIGURE 2. The mean 24-hour, diurnal, and nocturnal intraocular
pressure at baseline and annual time-points.
FIGURE 1. Kaplan-Meier survival curve for the study cohort on
travoprost monotherapy.
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travoprost, which involves remodeling of the extracellular
matrix,30–32 hence it is logical to assume a small increase in
eﬃcacy after the ﬁrst few months of treatment.
The mean 24-hour IOP reduction in patients treated
with travoprost was generally stable during the 5 years of
the study (Fig. 2). It may be of clinical value that the
24-hour eﬃcacy was quite uniform, without signiﬁcant
diﬀerences between the yearly 24-hour IOP curves. The
long-term consistency of IOP lowering may be important in
view of the fact that not all classes of antiglaucoma medi-
cations have shown persistence in eﬃcacy over the long-
term. For example b-blockers are reported to demonstrate a
long-term drift, probably due to modiﬁcations in the
number and aﬃnity of continuously blocked b-adrenergic
receptors.33,34 Considering the slow, insidious nature of
functional and anatomic deterioration in glaucoma, per-
sistence of the hypotensive eﬀect should be considered as an
advantage of antiglaucoma therapy.
In previous 24-hour studies with latanoprost, Quar-
anta et al35,36 observed that although this prostaglandin
induced a clinically meaningful 24-hour IOP reduction, the
hypotensive eﬀect was greater during the day, especially 8
to 12 hours after administration, albeit these results were
not statistically signiﬁcant. In the meta-analysis performed
by Stewart et al,1 however, the mean nighttime IOP
reduction was statistically lower than the daytime IOP
reduction for latanoprost, but not for travoprost. In the
present long-term 24-hour study, although mean nocturnal
IOP reduction with travoprost was somewhat lower than
the mean daytime IOP reduction, there was no signiﬁcant
diﬀerence between nighttime and daytime eﬃcacy.
Travoprost was generally well tolerated and no serious
drug-related adverse events were recorded throughout this
5-year study. Treatment-related adverse events were
observed in 18 patients (50%) during the course of the
study. These adverse events were consistent with those
expected with long-term prostaglandin therapy. Hyper-
pigmentation of the iris was the most common side eﬀect,
with a 5-year cumulative prevalence of 27.7%, which was
comparable with the 33.4% rate reported in a 5-year study
with latanoprost.37
Importantly, only baseline mean untreated 24-hour
IOP and treated 24-hour peak IOP were found to be sig-
niﬁcant parameters for predicting failure during the 5-year
follow-up of the study. As one would expect, the risk of
failure due to insuﬃcient IOP lowering increased in those
with higher baseline IOP. Thus, in POAG patients with
higher untreated mean 24-hour IOP at diagnosis, stepwise
therapy may be warranted earlier.
Our study also demonstrated that treated 24-hour
peak IOP was a risk factor for travoprost monotherapy
failure in POAG. This ﬁnding may apply for other pros-
taglandins and other agents, but this should be conﬁrmed
with future studies. It is still controversial whether peak 24-
hour IOP is an independent risk factor for progression in
POAG, or other glaucomas. Further, the role of peak 24-
hour IOP, or mean 24-hour IOP has not been adequately
evaluated in long-term trials to date. The Advanced Glau-
coma Intervention Study demonstrated with single IOP
measurements over time that a peak IOPr18mm Hg and a
mean IOP of 12.8mm Hg were the best combination to
prevent progression in patients with advanced POAG.38
Stewart et al39 also reported that peak IOP is an inde-
pendent risk factor for progression in treated POAG
patients followed-up retrospectively for 5 years. Similarly, a
5-year retrospective study by Hollo et al40 reported that the
TABLE 2. Mean 24-hour, Daytime, and Nocturnal IOP at Untreated Baseline and During Travoprost-treated Follow-up
No. Patients
at Risk 24-h IOP
P
(vs. Baseline)
Daytime
IOP
P
(vs. Baseline)
Nocturnal
IOP
P
(vs. Baseline)
Baseline (mm Hg±SD) 36 23.4±1.7 24.1±2.0 22.8±1.7
12mo (mm Hg±SD) 35 16.8±2.4 <0.01 17.0±2.8 <0.01 16.5±2.1 <0.01
24mo (mm Hg±SD) 34 16.8±2.5 <0.01 17.1±2.6 <0.01 16.6±2.3 <0.01
36mo (mm Hg±SD) 34 16.8±2.4 <0.01 17.2±2.7 <0.01 16.3±2.2 <0.01
48mo (mm Hg±SD) 34 16.7±2.5 <0.01 17.2±2.7 <0.01 16.3±2.4 <0.01
60mo (mm Hg±SD) 32 16.9±2.4 <0.01 17.1±2.7 <0.01 16.7±2.2 <0.01
P (among yearly time-points) 0.71 0.93 0.18
IOP indicates intraocular pressure.
TABLE 3. Calculated AUCs for Mean 24-hour, Daytime, and Nighttime IOP at Baseline and During Follow-up
No. Patients
at Risk
AUC for
24-h IOP
P
(vs. Baseline)
AUC for
Daytime IOP
P
(vs. Baseline)
AUC for
Nocturnal IOP
P
(vs. Baseline)
Baseline (±SD) 36 468.2±35.3 194.1±17 180.9±14.9
12mo (±SD) 35 335.5±49 <0.01 136.5±23 <0.01 132.3±17.2 <0.01
24mo (±SD) 34 336.7±49.1 <0.01 137.1±22 <0.01 133±18.5 <0.01
36mo (±SD) 34 335.3±48.6 <0.01 138.4±22.3 <0.01 130.5±17.5 <0.01
48mo (±SD) 34 334±50.4 <0.01 137.8±22.5 <0.01 129.9±18.9 <0.01
60mo (±SD) 32 338.3±48.7 <0.01 138.0±22.6 <0.01 133.7±18 <0.01
P (among yearly time-points) 0.71 0.82 0.08
AUC indicates area under the curve; IOP, intraocular pressure.
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peak IOP and the mean IOP are independent risk factors
for progression in treated exfoliative glaucoma patients.
These results are not consistent with other studies inves-
tigating the role of peak IOP established with single IOP
measurements over a long-term follow-up, in which peak
IOP was not found to be an independent risk factor for
progression.41–43
To date only one previous study44 analyzed retro-
spectively the eﬀect of 24-hour peak IOP on long-term
progression in POAG. In that study 24-hour peak IOP was
documented to be an independent risk factor for pro-
gression, and a 24-hour peak IOP below 18mm Hg ensured
a 78% nonprogression rate in treated POAG patients after
5 years of follow-up. Similarly, in the present prospective
study that used travoprost monotherapy, stable patients
exhibited a mean treated 24-hour IOP peak of 17.8±
1.01mm Hg, whereas progressive patients (who were with-
drawn from the study) demonstrated a mean treated
24-hour peak IOP of 19.4±0.89mm Hg (P<0.01).
A limitation of this study is the relatively small sample
size. This is due to signiﬁcant diﬃculties in enrolling a large
cohort of patients with a long follow-up for 24-hour
monitoring. Small sample size could have limited the power
of statistical analysis, especially regarding the evaluation of
parameters as risk factors for failure. Further, progression
was evaluated by the principal investigator and relied upon
a number of clinical criteria (eg, visual ﬁeld, optic disc
appearance, etc.) and not by a masked observer relying on
visual ﬁelds, or disc photographs. This approach, however,
reﬂects standard clinical practice used in an academic
glaucoma service. Our results apply only to POAG and not
to other glaucomas that may be more diﬃcult to control
with monotherapy (eg, exfoliative glaucoma, chronic angle-
closure glaucoma, etc.). It should also be noted that
because our participants had mild POAG, the results might
not necessarily apply to patients with more advanced dis-
ease whose IOP may be less likely to be controlled with
travoprost monotherapy. Another limitation of the study
was the incomplete assessor masking: the clinician who
performed the IOP measurements knew that the patient
was a participant of a long-term travoprost eﬃcacy study
but was masked to the previous baseline or treated IOP
data. Although the importance of compliance with medi-
cation was stressed to all patients in each visit, no formal
method of compliance assessment was used in this study.
Such methodology reﬂects the norm in medium and long-
term drug eﬃcacy studies, as well as the real life situation in
typical academic glaucoma centers.
Despite these limitations, our long-term study has
demonstrated that travoprost monotherapy can con-
sistently control the 24-hour IOP in a signiﬁcant proportion
of POAG patients. Future research is needed to evaluate
the long-term 24-hour eﬃcacy of all therapy options in
glaucoma. Such evidence may optimize glaucoma care and
reduce the rate of glaucomatous visual loss.
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